The Portuguese pharmaceutical Hovione, market leader in spray drying technology and particle engineering, has partnered with the Danish company Zerion Pharma to commercialize Dispersome, a technological platform aimed at improving drug solubility.

The solution increases the solubility of drugs through the use of an excipient of natural origin, which facilitates greater and faster absorption of the drug. In this way, it is possible to reduce the dose of each tablet, allowing patients to take smaller tablets, or to take fewer doses. Hovione thus strengthens its commitment to innovative solutions that respond to the greatest challenges of the global pharmaceutical industry.

The announcement of the partnership with Zerion comes after Hovione announced a new investment of 146 million euros in the expansion of industrial facilities in Portugal, Ireland and New Jersey, in the USA, as part of a global growth plan that will increase the company's capacity by about 25%.

Hovione is investing in new assets, but also in innovative technologies, with the aim of responding to the needs of its customers in terms of integrated and differentiated services in the production of active principles, in particle engineering and, more recently, in drug production. This growth will be reflected in the attraction of talent at a national and international level with the creation of more than 300 new jobs, of which 150 are in Portugal.